This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	Microfibrillar associated protein 5 (MFAP5; MAGP2)	<p>A study in cancer patients and in cell culture suggests that antagonizing MAGP2 could help treat ovarian cancer. In ovarian cancer patients, high <i>MAGP2</i> expression correlated with greater microvessel density in tumors and poor survival compared with low <i>MAGP2</i> levels. In cell culture, treatment with recombinant MAGP2 increased adhesion and survival of tumor cells compared with no treatment. Next steps include confirming <i>MAGP2</i> expression as a prognostic marker in larger cohorts and developing antibody therapeutics against MAGP2.</p> <p>SciBX 3(2); doi:10.1038/scibx.2010.48 Published online Jan. 14, 2010</p>	Patents pending; available for licensing from the National Cancer Institute	<p>Mok, S.C. <i>et al. Cancer Cell</i>; published online Dec. 8, 2009; doi:10.1016/j.ccr.2009.10.018 Contact: Michael J. Birrer, National Cancer Institute, Rockville, Md. e-mail: mbirrer@partners.org Contact: Samuel C. Mok, The University of Texas M.D. Anderson Cancer Center, Houston, Texas e-mail: mbirrer@partners.org</p>